Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors

Br J Dermatol. 2023 Dec 20;190(1):138. doi: 10.1093/bjd/ljad342.
No abstract available

Publication types

  • Comment

MeSH terms

  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / adverse effects
  • Interleukin-13
  • Interleukins
  • Melanoma* / drug therapy
  • Pemphigoid, Bullous* / chemically induced
  • Pemphigoid, Bullous* / drug therapy
  • Pemphigoid, Bullous* / immunology

Substances

  • Interleukin-13
  • Immune Checkpoint Inhibitors
  • Interleukins